[HTML][HTML] Minimal residual disease detection in acute lymphoblastic leukemia
A Kruse, N Abdel-Azim, HN Kim, Y Ruan… - International journal of …, 2020 - mdpi.com
Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia
cell population that gives rise to relapse of the disease. The detection of MRD is critical for …
cell population that gives rise to relapse of the disease. The detection of MRD is critical for …
Acute lymphoblastic leukemia
M Onciu - Hematology/oncology clinics of North America, 2009 - Elsevier
Acute lymphoblastic leukemia and lymphoblastic lymphoma constitute a family of genetically
heterogeneous lymphoid neoplasms derived from B-and T-lymphoid progenitors. Diagnosis …
heterogeneous lymphoid neoplasms derived from B-and T-lymphoid progenitors. Diagnosis …
[HTML][HTML] EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
JJM Van Dongen, L Lhermitte, S Böttcher, J Almeida… - Leukemia, 2012 - nature.com
Most consensus leukemia & lymphoma antibody panels consist of lists of markers based on
expert opinions, but they have not been validated. Here we present the validated EuroFlow …
expert opinions, but they have not been validated. Here we present the validated EuroFlow …
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted …
N Gökbuget, M Kneba, T Raff… - Blood, The Journal …, 2012 - ashpublications.org
Quantification of minimal residual disease (MRD) by real-time PCR directed to TCR and Ig
gene rearrangements allows a refined evaluation of response in acute lymphoblastic …
gene rearrangements allows a refined evaluation of response in acute lymphoblastic …
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission …
AH Goldstone, SM Richards… - Blood, The Journal …, 2008 - ashpublications.org
An international collaboration was set up to prospectively evaluate the role of allogeneic
transplantation for adults with acute lymphoblastic leukemia (ALL) and compare autologous …
transplantation for adults with acute lymphoblastic leukemia (ALL) and compare autologous …
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII …
DI Marks, EM Paietta, AV Moorman… - Blood, The Journal …, 2009 - ashpublications.org
The biology and outcome of adult T-cell acute lymphoblastic leukemia are poorly
understood. We present here the clinical and biologic features of 356 patients treated …
understood. We present here the clinical and biologic features of 356 patients treated …
Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the …
Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission is a
standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute …
standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute …
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the …
T Flohr, A Schrauder, G Cazzaniga… - Leukemia, 2008 - nature.com
Detection of minimal residual disease (MRD) is the most sensitive method to evaluate
treatment response and one of the strongest predictors of outcome in childhood acute …
treatment response and one of the strongest predictors of outcome in childhood acute …
Treatment of adult acute lymphoblastic leukemia
N Gökbuget, D Hoelzer - Seminars in hematology, 2009 - Elsevier
Treatment results in adult acute lymphoblastic leukemia (ALL) have improved considerably
in the past decade, with an increase of complete remission rates to 85% to 90% and overall …
in the past decade, with an increase of complete remission rates to 85% to 90% and overall …
[HTML][HTML] Multiparametric flow cytometry for MRD monitoring in hematologic malignancies: clinical applications and new challenges
G Riva, V Nasillo, AM Ottomano, G Bergonzini… - Cancers, 2021 - mdpi.com
Simple Summary In hematologic cancers, Minimal Residual Disease (MRD) monitoring,
using either molecular (PCR) or immunophenotypic (MFC) diagnostics, allows the …
using either molecular (PCR) or immunophenotypic (MFC) diagnostics, allows the …